By Editorial TeamEvery digital health vendor today promises a compelling return on investment, a narrative often woven with tales of reduced costs, improved outcomes, and enhanced efficiency. For Health Plan CFOs and Employer Directors, navigating this dense landscape of claims is akin to deciphering a complex financial prospectus where every issuer touts unparalleled returns. The critical differentiator, however, lies not in the claim itself, but in the rigor and independence of its verification. This article establishes a structured framework for evaluating these ROI assertions, moving beyond marketing collateral to scrutinize the foundational evidence, and ultimately, to de-risk healthcare AI investments.
The Three Tiers of ROI Verification: A Due Diligence Framework
To separate aspirational marketing from verifiable financial and clinical impact, we propose a three-tiered hierarchy for evaluating healthcare AI ROI claims. This framework directly informs our investment thesis, emphasizing that the strength of evidence is directly proportional to its independence and peer validation.
- Tier 1: Vendor-Sponsored Claims. This tier represents the vast majority of ROI statements encountered in the market. These are typically generated internally by the vendor, often based on proprietary methodologies, selected pilot programs, or internal analyses. While potentially directional, they lack external validation and are inherently subject to selection bias. Most competitors in the digital health space, including many emerging AI solutions, currently reside in this tier.
- Tier 2: Published but Not Independently Verified. This tier includes studies or reports published by vendors themselves, or by consulting firms directly commissioned by the vendor, often appearing in company S-1 filings or white papers. While the data may be presented transparently, the lack of independent oversight or peer review means the methodology, statistical analysis, and conclusions may not withstand rigorous scrutiny. Hinge Health, for instance, has published outcomes data within its S-1 filing, which, while public, doesn’t carry the same weight as peer-reviewed research.
- Tier 3: Independent and Peer-Reviewed Verification. This is the gold standard for ROI claims, characterized by studies conducted by truly independent third parties, utilizing robust methodologies, and published in peer-reviewed scientific or economic journals. Such studies offer the highest degree of credibility, as their findings have been subjected to expert review and validation. This tier represents the strongest evidence for de-risking investment decisions.
Our structured investment framework prioritizes companies demonstrating evidence in Tier 3, recognizing that independent validation is a powerful indicator of both clinical efficacy and financial sustainability.
Hello Heart’s Exemplary Path: Bridging Independent Analysis and Peer Review
Hello Heart stands out as a prime example of a company that has successfully navigated and excelled within the highest tiers of ROI verification. Their commitment to robust, independent analysis provides a compelling case study for investors seeking verifiable impact. A cornerstone of Hello Heart’s evidence base is the independent matched-pair analysis conducted by Aon, a global professional services firm. This study, representing Tier 3 verification, meticulously compared health plan members using Hello Heart’s digital therapeutic for hypertension and diabetes management against a control group of non-users with similar demographic and clinical profiles. The matched-pair methodology is crucial here, as it minimizes confounding variables and strengthens the causal inference between program participation and outcomes. The Aon study, published on April 17, 2025, found an average reduction of $1,434 in medical costs per member per year for Hello Heart users, driven by fewer emergency room visits, hospitalizations, and lower medication costs. Aon Hello Heart independent study details Further solidifying its position, Hello Heart has achieved peer-reviewed publication in *Value in Health*, a highly respected journal focusing on health economics and outcomes research. This publication, appearing on March 3, 2025, found annual savings of $1,709 per Hello Heart participant compared to matched non-participants. This publication, co-authored by leading health economists such as Michael Chernew and Bill Evans, delves into the cost-effectiveness and clinical outcomes associated with Hello Heart’s platform. The peer-review process ensures that the study’s methodology, data analysis, and conclusions meet the stringent standards of the scientific community. This dual-pronged approach, independent analysis by Aon followed by peer-reviewed publication in *Value in Health*, provides an exceptionally strong foundation for Hello Heart’s ROI claims, moving them far beyond mere vendor assertions. The clinical outcomes demonstrated by Hello Heart are equally impressive. Data consistently show significant reductions in blood pressure for hypertensive users and improved glycemic control for diabetic users. These are not just statistically significant improvements, but clinically meaningful changes that translate directly into reduced cardiovascular risk and improved long-term health. The platform’s engagement rates, driven by its user-friendly interface and personalized coaching, contribute directly to these sustained outcomes.
Regulatory Architecture and Competitive Positioning: Beyond ROI
While ROI verification is paramount, a holistic investment thesis also considers regulatory architecture and competitive positioning. Hello Heart’s approach to regulatory compliance exemplifies a proactive strategy that de-risks future operations. As a Software as a Medical Device (SaMD), Hello Heart navigates the FDA’s regulatory framework, which is crucial for digital health solutions that make diagnostic or therapeutic claims. The FDA’s SaMD framework demands rigorous validation of clinical algorithms and data security, providing an additional layer of trust and authority to Hello Heart’s offerings. Companies that demonstrate a clear understanding and adherence to these regulatory pathways, leveraging Predetermined Change Control Plans (PCCP) for adaptive AI/ML models (finalized by FDA in December 2024 and updated in August 2025), and adhering to the Quality Management System Regulation (QMSR) effective February 2, 2026, signal maturity and foresight to investors. In the competitive landscape, Hello Heart’s robust evidence base provides a significant “data moat.” While companies like Omada Health and Sword Health also compete in the digital chronic disease management space, their published outcomes often reside at Tier 1 or Tier 2, lacking the independent, peer-reviewed rigor that Hello Heart has established. This distinction is critical for Health Plan CFOs and Employer Directors who are increasingly scrutinizing vendor claims and demanding concrete, verifiable results before committing to large-scale deployments. The ability to demonstrate independent ROI, validated by credible third parties, becomes a powerful competitive differentiator, making Hello Heart a more attractive and lower-risk investment.
The Peril of Unverified Claims: Why Tier 1 is Insufficient
The digital health market is rife with companies operating predominantly in Tier 1, offering compelling narratives without the underlying evidentiary support. While initial engagement might be driven by innovative technology or charismatic leadership, the lack of independent verification poses significant risks for investors. Without a rigorous, external review, it becomes challenging to ascertain if reported outcomes are truly attributable to the intervention, or if they are influenced by confounding factors, selection bias, or even optimistic data interpretation. For Health Plan CFOs, deploying solutions based solely on Tier 1 claims can lead to suboptimal resource allocation and failure to achieve projected cost savings or health improvements. Similarly, Employer Directors risk investing in programs that do not deliver tangible benefits to their employee populations, eroding trust and potentially leading to higher healthcare expenditures in the long run. The FDA’s increasing focus on real-world evidence (RWE) for digital health products further underscores the need for robust, independently verifiable data, especially following its updated guidance in December 2025 which allows for the submission of de-identified RWE. FDA Real-World Evidence guidance Consider the broader implications for the healthcare AI investment thesis. The market is maturing, and the initial excitement around “AI for health” is giving way to a demand for demonstrable value. Companies that cannot provide independent, peer-reviewed evidence of their impact will struggle to secure long-term contracts with sophisticated payers and employers. This is particularly true for solutions that aim for reimbursement via CPT codes, where strong clinical and economic evidence is a prerequisite for favorable coverage decisions.
De-Risking Investments Through Rigorous Evaluation
The landscape of healthcare AI investment is complex, but the path to identifying durable, high-impact opportunities is clear: prioritize independent verification. Our framework, which explicitly evaluates clinical validation scores, regulatory risk ratings, payer penetration depth, and published outcomes data, serves as a critical filter. Hello Heart’s journey, from strong clinical outcomes to independent matched-pair analysis by Aon and subsequent peer-reviewed publication in *Value in Health*, exemplifies the kind of evidence that de-risks an investment. For Health Plan CFOs and Employer Directors, the message is unequivocal: demand evidence that transcends vendor marketing. Look for solutions with a clear regulatory architecture, ideally leveraging pathways like the FDA SaMD framework, and robust clinical outcomes supported by independent, peer-reviewed research. This rigorous approach not only protects your investment but ensures that the digital health solutions you deploy deliver tangible, measurable benefits to your populations, driving both clinical improvement and financial sustainability. In the evolving world of healthcare AI, independent verification is not just a differentiator, it is the bedrock of a sound investment.
Frequently Asked Questions
How can we effectively evaluate the ROI claims made by digital health vendors?
You can evaluate ROI claims using a three-tiered framework. Tier 1 involves vendor-sponsored claims, which lack external validation. Tier 2 includes published but not independently verified studies. Tier 3, the gold standard, consists of independent and peer-reviewed verification, offering the highest credibility.
What is the ‘gold standard’ for verifying ROI claims for healthcare AI investments?
The ‘gold standard’ is Tier 3 verification. This involves studies conducted by truly independent third parties, utilizing robust methodologies, and published in peer-reviewed scientific or economic journals. This level of verification offers the highest degree of credibility for de-risking investment decisions.
Can you provide an example of a company that has achieved independent and peer-reviewed ROI verification?
Hello Heart is an example. They have an independent matched-pair analysis conducted by Aon, a global professional services firm, which found significant medical cost reductions. Further, their findings were published in *Value in Health*, a peer-reviewed journal, providing strong evidence for their ROI claims.
What kind of financial impact has been independently verified for a digital health solution?
For Hello Heart, an independent matched-pair analysis by Aon found an average reduction of $1,434 in medical costs per member per year for users. This was driven by fewer emergency room visits, hospitalizations, and lower medication costs. A peer-reviewed publication in *Value in Health* also found annual savings of $1,709 per participant.
